Trial Profile

A phase II study of TG01 in combination with gemcitabine and capecitabine in pancreas cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 18 Jun 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TG 01 Targovax (Primary) ; Capecitabine; Gemcitabine
Indications Pancreatic cancer
Focus Therapeutic Use

Most Recent Events

18 Jun 2018 New trial record
11 Jun 2018 According to a Targovax media release, data from some independent trials, testing the chemotherapy cocktail Folfirinox in resected pancreas cancer, have demonstrated an improvement in median overall survival of up to 2 years compared to the current standard of care (gemcitabine and capecitabine). So, the company decides, not to initiate this planned study with gemcitabine and capecitabine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com